title: Alteration in the GABAergic network of the prefrontal cortex in a potential animal model of psychosis.
abstract: The GABAergic input on cortical pyramidal cells has an important influence on the firing activity of the cortex and thus in regulating the behavioural outcome. The aim of the current study was to investigate the long-term neuroplastic adaptation of the GABAergic innervation pattern after an early severe systemic impact. Therefore 40 Mongolian gerbils (Meriones unguiculatus) were either reared under impoverished (IR) or enriched rearing conditions (ER) and received a single early (+)-methamphetamine (MA) challenge (50 mg/kg i.p.) or saline on postnatal day 14. The density of perisomatic immunoreactive GABAergic terminals surrounding layers III and V pyramidal neurons was quantified as well as the overall GABAergic fibre density in layers I/II and V of the medial prefrontal cortex (mPFC) of young adult animals (90 days). We found that IR in combination with an early MA administration led to a significant decrease in GABAergic bouton densities while the overall GABAergic fibre density increased in all investigated layers. The results indicate a shift in inhibition from somatic to dendritic innervation of pyramidal neurons in this potential animal model of psychosis. We conclude that IR combined with early MA trigger changes in the postnatal maturation of the prefrontal cortical GABAergic triggers innervation, which may interfere with proper signal processing within the prefrontal neural network.
authors.affiliation: Department of Neuroanatomy, Faculty of Biology, University of Bielefeld, Bielefeld, Germany. sbrummelte@uni-bielefeld.de
authors.forename: S
authors.initials: S
authors.lastname: Brummelte
authors.forename: J
authors.initials: J
authors.lastname: Neddens
authors.forename: G
authors.initials: G
authors.lastname: Teuchert-Noodt
mesh_terms: D000375:Aging / Q000502:physiology; D000818:Animals; D002454:Cell Differentiation / Q000502:physiology; D004195:Disease Models, Animal; D018765:Dopamine Uptake Inhibitors / Q000009:adverse effects; D004779:Environment Design; D005849:Gerbillinae; D007395:Interneurons / Q000378:metabolism / Q000473:pathology; D008297:Male; D008694:Methamphetamine / Q000009:adverse effects; D009415:Nerve Net / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D017397:Prefrontal Cortex / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D017729:Presynaptic Terminals / Q000378:metabolism* / Q000473:pathology; D011618:Psychotic Disorders / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D017966:Pyramidal Cells / Q000378:metabolism* / Q000473:pathology; D012683:Sensory Deprivation / Q000502:physiology; D013569:Synapses / Q000378:metabolism / Q000473:pathology; D009435:Synaptic Transmission / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
chemical_list: D018765:Dopamine Uptake Inhibitors; D008694:Methamphetamine; D005680:gamma-Aminobutyric Acid